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Abstract  
Background: Occurrence of mutations within the major antigenic alpha determinant region of hepatitis B 
surface antigen (HBsAg can alter HBV antigenicity resulting in   failures in diagnosis, vaccine and hepatitis B 
immunoglobulin therapy.  
Objective: This study aimed at detection of mutations in the “a” determinant region of HBV surface antigen 
among voluntary blood donors in Kenya.  
Design: A cross sectional study involving serology and molecular techniques 
Settings: This study involved analysis of samples from blood transfusion centers 
Subjects: A total of 301 blood samples from donor blood were collected for the study.  
Methods: Sero-status for HBsAg was determined using Enzyme-Linked Immunosorbent Assay (ELISA). A 
fragment of the S gene including the "a" determinant was amplified by PCR from the HBsAg positive samples 
and sequenced for mutation analysis. Mutations and phylogenetic analyses were performed using Mega 6 
software, Bioedit software and GENETYX® software version 9.1.0. 
Results: Out of the 301 samples tested 69/301 (22.9%) were Polymerase Chain Reaction (PCR) positive 
including 2/69(2.9%) were sero-negative for HBsAg. All isolates were genotype A, sub-genotype A1. A total of 
29 mutations were observed of which 37.9% were located within the “a” determinant. Mutations T143M and 
K122R were the most frequent in this study. Escape mutations associated with diagnostic failure, vaccine and 
immunoglobulin therapy escape were also identified.  
Conclusions: These findings are important for policies related to vaccine implementation and therapeutic and 
diagnostic guidelines.  
Keywords: Escape mutants, genotype, hepatitis B virus, antigenic determinant, surface antigen. 
 
1 Introduction 
Hepatitis B virus infection (HBV) is a major public health concern especially in Africa, Middle East and Asia 
(Akbar et al., 2004, McMahon, 2005). More than 4 billion people have had contact with HBV worldwide (Ying-
Hui, 2012). Of these, about 360 million people are chronic carriers of HBV that can cause death from liver 
cirrhosis and hepatocellular carcinoma (HCC) (Lavanchy, 2004; WHO, 2015).  
 
Though HBV is a DNA virus, it replicates via reverse transcriptase (polymerase enzyme) which has no proof-
reading activity leading to the generation of mutations occurring naturally during infections (Kramvis 2014). 
  Hepatitis B surface antigen (HBsAg) is a primary target for diagnosis and immunoprophylaxis of HBV 
infection (El-sherif et al., 2007). The HBsAg which is a 226 amino acid sequence   contains a highly 
conformational, hydrophilic domain known as the “a” determinant located at positions between aa124-aa147 
within the Major Hydrophilic Region (MHR; aa110-aa165 (Hu et al., 2009). The dominant epitopes of “a” 
determinant are the targets of neutralizing antibodies used in active, passive immunization and in diagnostic 
assays. (Kay et al., 2007). Mutations in this region can reduce the binding affinity between the HBsAg and 
antibody to the HBsAg resulting in weak reactivity of serological assays. Although, mutations have been 
described in all the four open reading frames (ORFs) of the HBV, S escape mutants is the most worrying since it 
may be spread by blood transfusion. HBV DNA detection by nucleic acid amplification technology (NAT) is not 
mandatory for blood donor screening in many countries, especially in those areas where the prevalence of S 
escape mutants is projected to be high (Fischinger et al., 2010). It is imperative that the prevalence and types of 
variants of the “a” determinant  found in the population be monitored, because this will affect policy decisions 
relating to vaccine and diagnostic reagents design (Zuckerman, 2000; Francois et al., 2001).To date cases of 
blood donations with diagnostic escape  mutations not detected by HBsAg screening assay have been reported 
(Levicnic, 2004). Therefore, we aimed at detection of mutations in the “a” determinant region within the S gene 
among voluntary blood donors in Kenya.  
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2. Methods 
This study was cross-sectional where 301 plasma samples were collected from blood transfusion centers in 
Kenya. The samples were then transported to Kenya Medical Research Institute (KEMRI) HBV laboratory 
through cold chain and stored at -80°C till use. The presence of HBsAg was tested using Hepanostika HBsAg 
Ultra (BioMérieux, Lyon, France) kit as per the manufacturer’s instructions.  
 
Viral DNA was extracted from 200µl aliquoted plasma using a QIAamp DNA Mini Kit (QIAGEN, Hilden, 
Germany) according to the manufacturer’s instructions. Extracted DNA was eluted in 60µl DNAse free water 
and stored at -20C till use. A 780 base pair (bp) fragment of HBV was amplified by nested PCR using Kemtaq 
DNA polymerase kit from Kenya and HBV specific primer pair S1(LLf) 5’-TCCTGCTGGTGGCTCCAG-3’as 
sense primer and S1(LLr) CGTTGACATACTTTCCAATCAA)-3’ as anti-sense primer (Osilowy et al., 2009). 
Nested PCR was performed by an ABI Thermocycler 9600 system (Applied Biosystems, USA). The conditions 
for first round PCR consisted of 94 °C for 5 min; followed by 40 cycles at 94 °C for 4 min; 94 °C for 45 seconds 
min; and 46 °C for 30 seconds; and final extension at 72 °C for 10 min. A total volume of 25µL was amplified in 
first-round, containing QIAGEN PCR buffer, 0.5µM of each primer, 0.2 mM dNTP mix, 2.5 U Taq polymerase 
(KEMRI Taq) and 10µL of extracted DNA. The second PCR round was done under the same conditions except 
that annealing was done at 50°C with 10µl of the first-round product using the primer S2nLLf 5’- 
ACCCTGYRCCGAACATGGA-3’as sense primer and S2 nLLr) 5’- CAACTCCCAATTACATARCCCA -3’ as 
anti-sense primer (Osilowy et al., 2009). PCR-amplified products (10 µl) were separated by electrophoresis on 
2% agarose gel, stained with ethidium bromide and viewed under ultraviolet light.  
 
HBV DNA positive samples were sequenced using a big dye terminator and the obtained nucleotide sequences 
edited and aligned using BioEdit sequence alignment editor software version 5.0.9 (Hall, 1999). The newly 
sequenced (query sequences) were aligned along with reference sequences available in the gene bank. This was 
followed by CLUSTAL W multiple sequence alignment (Thompson, 1994). After some manual editing by 
stripping the ends the phylogenetic and molecular evolutionary analyses were conducted using MEGA6 (Tamura 
et al., 2013). Maximum parsimony test was used for phylogenetic reconstructions. The phylogenetic tree was 
constructed using MEGA 6. Bootstrapping was performed using 1000 replicates. The nucleotide sequences 
detected in this study were deposited in the GenBank and these are their accession numbers (KR816101-
KR816152). The aligned nucleotide sequences were translated into amino acid sequences using GENETYX® 
software version 9.1.0. to allow for determination of any mutations  within the S protein.  
 
Approval to conduct the study was granted by Kenya Medical Research Institute (Kemri) Scientific and Ethics 
Review Unit (SERU) (SSC NO. 2443) and Regional Blood Transfusion Centre. 
 
RESULTS 
Hepatitis B   Virus DNA PCR was done in 301 samples; PCR amplified 69(22.9%) samples. Of these 2 (2.9%) 
were sero-negative for HBsAg. Table 1summarizes the ELISA and PCR results. 
 
The PCR products obtained were sequenced and 52 (75 %) successfully genotyped. A phylogenetic tree was 
generated for all 52 nucleotide sequences as shown in Figure 1. The predominant genotype was A. 
 
Prevalence of HBV escape mutations   
A total 29 mutations were observed in the present study. Eleven of the 29 mutations (37.9%) were located within 
the “a” determinant (124-147), whereas 63.6% (7/11) were in the first loop (positions 120-137) and 36.4% (4/11) 
in the second loop (positions 139-147). The amino acid substitutions detected in the “a” determinant of HBsAg 
included mutations at positions M133I, K133E, M134S, and F137L and T143M in 5 sequences .The most 
frequent mutations observed were T143M and K122R  detected each  in (3/52) 5.8%  of sequences . 
 
Twenty sequences (38.5%) had  amino acid  changes  outside the ‘a’ determinant identified among them;  
Y161F, E164G W165L, S167L, V184A, T189I, S193L and  A194V.In addition  13 had a single mutation 
(65.0%), 7(35%) had double to triple mutations. 
 
4. Discussion 
In this study we report on HBsAg mutations and HBV genotypes among voluntary blood donor population in 
Kenya . Genotype A sub-genotype A1 was observed in all the HBV DNA positive plasma samples tested. This 
was comparable with other published data in Kenya (Kwange et al., 2013). Genotype A was found to be 
predominant   in Kenya followed by genotypes E and D (Mwangi et al., 2008; Ochwoto et al., 2013).  This 
probably suggest the trends in HBV genotypes has remained the same especially in this study population 
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This study also identified mutations of interest in HBV genome. Vaccine escape, immunotherapy and diagnostic 
escape mutants within and outside the “a” determinant region of HBsAg were both detected among the volunteer 
blood donor population. Since the basis for effective prevention of HBV infections lies in the use of effective 
vaccination and diagnostic programming, results of this study therefore  provides relevant and valuable 
information on genetic variability of HBV.  
 
This study found different mutations in the S region of HBV genomes, where the percentage of samples with 
these mutations was 29/52(42.3%). 
 
In comparison to studies that have been conducted in Kenya Kwange et al., 2013 reported S gene mutations 
including K122R, T189I and S210R in samples collected from various parts of the country. However, they did 
not report any amino acid substitution in “a” determinant. Our finding showed that 37.9% mutations were 
located within the “a” determinant 124-147. 
 
In a study carried out in Iran (Moradi et al., 2012) the following amino acid changes were reported in genotype 
D: Y100F, L109R, I110L, G112R, S117I, P120S/T, R122K/T, M133I, Y134H, T140I, S143L, G145R, G159R, 
and E164V. Five of 40 mutations (12.5%) occurred in ‘‘a’’ determinant region and they included; M133I, 
Y134H in the first loop of ‘‘a’’ determinant and the rest of substitutions including T140I, S143L and G145R 
occurred in the second loop of ‘‘a’’ determinant. In this study 11 of the 29 mutations (37.9%) were located 
within the “a” determinant, 63.6% (7/11) in the first loop (amino acid positions 120-137) and 36.4% (4/11) in the 
second loop (amino acid positions 139-147).The only similarity that is seen between the two studies is amino 
acid substitutions at M133I which is associated with vaccine escape. The differences might be attributed to the 
difference in genetic variability of HBV.  
 
Our study reported a pattern of more frequent mutations including K122R and T143M. A mutation K122R 
substitution was detected in three samples within the MHR (aa110-aa165) this is a polymorphism typically 
linked with determining d/y sub-serotype specificity (Martin et al., 2010 ;Amponsah et al., 2013). Two previous 
studies in Kenyan; one by Ochwoto et al., (2013), conducted among liver disease patients and that of Kwange et 
al, 2013 among a blood donor population reported mutations in HBV genome. The current study, however 
reports diversity of mutations within a larger study population and diverse geographical localities in Kenya. 
 
Moreover, Yong et al., 2012 reported mutations at positions D99N, Y100F, Q101R/H, L110I, T113S, S114T, 
S117T, T118M, I126T/V, W165L, and V168A. Our findings showed different feature of mutations with four 
similar mutations at positions Q101H, K122R, T143M, and W165L. This difference could be due to high 
variability of geographical location. A known mutation T143M frequent in this study was reported in Indonesian 
blood donors and has been associated with   altering antigenic properties of variant HBsAg, this mutant also has 
been associated with problems in diagnostic assays and escape to vaccine and HBIg therapy as reported by Le et 
al., 2010. Here, T143M was found in 3 out of 52 samples. Among these samples, two samples were sero-
negative for HBsAg but positive for the corresponding HBV- DNA. Repeat testing of these samples consistently 
gave negative results despite using different test kits including ELISA and rapid tests. In addition these samples 
were observed to have mutations; T143M, M133I respectively. Since these substitutions has been associated 
with   failure of HBIg therapy and problems in detection assays (Ren et al., 2006). It is likely that failure to 
detect positivity by serology on the samples could be due to mutations. Such reports of false-negative diagnostic 
results due to HBsAg mutants have been described previously (Coleman, 2006; Rebecca, 2011).This could also 
be due to low concentration of analyte.We  however did not carry out viral load testing due to unavailability of 
resources. 
 
Mutation M133I observed in the present study in one sample was reported in a Spanish study and   is associated 
with the failure of HBIg therapy since it causes a reduced HBsAg affinity to anti-HBs and reduced HBsAg 
detection in commercial diagnostic assays (Le et al.2010). Other different amino acid substitutions G130S, 
F137L, T114S, T114K and M134S within MHR were also found in the samples from HBV subtype A1. The 
effects of these variations on the HBsAg are unknown. The other important finding in the current study is the 
magnitude of mutations. In total, 29 mutations were detected in 20 of the 52 samples analyzed. These mutations 
were distributed across the sequenced genome fragment including 11 of 29 in ‘a ‘determinant, 7 and 4 of 11 in 
the first and second loop respectively. Since these samples were collected from across different sites in Kenya, 
this probably demonstrates an underlying genotypic mutation dynamics of HBV occurrence in the population. 
The major concern arising from HBsAg mutations is the 3 clinical related outcomes which includes; diagnostic 
escape mutants  affecting reliability of results of various diagnostic assays, escape from vaccine-induced 
immunity, antiviral resistance and passively transferred neutralizing responses in newborn babies or liver-
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transplant recipients (Sayiner et al.,2007;Ma, and Wang, 2012). Considerably, these events could be taking place 
in our population undetected, except for blood transfusion, work place, and infants’ vaccination; there is no 
universal policy on HBV prevention in Kenya. This situation could be similar in most countries across Africa. 
Both genotype variability and mutations are important consideration in development of effective vaccines. 
Hepatitis B virus has been shown to display a certain geographical distribution. Our study however indicates a 
single genotype on all the samples collected from different regions in Kenya. This is however understandable 
since genotype A has been shown to be the most prevalent. Whereas genotypes have been shown to influence the 
disease progression and treatment responses (Bartholomeusz and Schaefer, 2004; Chotiyaputta and Lok, 2009). 
A strong link between HBV genotype and the natural history of disease as well as the better response to 
interferon treatment in genotype A is encouraging. Given the high prevalence of HBV in Kenya, and in Africa, 
where blood transfusion is a critical intervention monitoring and prevention of infections is crucial. While 
mutations in the major hydrophilic region of HBV Surface antigen have been reported in developing countries, 
largely, there is limited data on Hepatitis B in Kenya partly due to lack of official programming, universal testing 
strategy and prioritized research. Currently, the public health impact of Hepatitis is drawing attention and the 
future is likely to see more efforts and focused momentum towards hepatitis. Availability of information on 
mutations and genetic variants of HBV in this region is required to inform development of clinical and 
surveillance mechanisms.  
 
5. Conclusions 
Genotypes A, sub-genotype A1 was found to be prevalent.  Escape mutations which have been associated with 
diagnostic failure, vaccine escape and immunoglobulin therapy are present within the population. Other than 
T143M, different aa substitutions G130S, F137L, T114S, T114K and M134S within MHR were also found in 
the samples from HBV subtype A1. The effects of these variations on the HBsAg are unknown and there is need 
for further studies. This finding is an important monitoring tool in guiding future policies related to laboratory 
diagnostic procedures.  
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Table 1: Prevalence of HBV-DNA in Donor Blood  
Variable HBsAg status HBV DNA status 
Positive 67(22.2%) 69(22.9%) 
Negative 234(77.8%) 232(77.1%) 
Total 301 301 
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Figure 1: Phylogenetic analysis based on nucleotide sequencing of the S region. The tree contains sequences 
from 52 samples and a set of representative sequences belonging to genotypes and subgenotypes retrieved from 
Genebank. The phylogenetic tree was constructed using the neighbor-joining method in Clustal W 
 
Mutations in the ‘‘a’’ determinant domain of HBV isolates. 
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Figure 2: Multiple sequence alignment with hierarchical clustering based on the protein sequences of the MHR 
of HBsAg from genotype A. Dots indicate identity to the genotype A consensus. 
 
and  
 
Figure 3: Multiple sequence alignment with hierarchical clustering based on the protein sequences of the MHR 
of HBsAg from genotype A. Dots indicate identity to the genotype A consensus. 
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Table 2: Mutation analysis of the ‘‘a’’ determinant  in HBV donors  
Amino acid position wildtype mutation Frequency 
101 Q H 1 
114 T K 1 
114 T S 1 
118 T A 1 
122 K R 3 
130 G S 1 
133 M I 1 
133 K E 1 
134 M S 1 
137 F L 1 
143 T M 3 
146 N K 1 
149 C R 1 
159 A V 1 
161 Y F 1 
164 E G 1 
165 W L 1 
167 S L 2 
184 V A 2 
189 T I 1 
193 S L 1 
A194 A V 1 
 
 
